ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis €67.25 0.00 (0.00%) As of 08/20/2024 Add Compare Share Share Stock Analysis Stock Analysis About MorphoSys Stock (ETR:MOR) Get MorphoSys alerts:Sign Up Key Stats Today's Range€66.70▼€67.3050-Day Range€67.25▼€67.2552-Week Range€14.52▼€69.75Volume5,144 shsAverage Volume153,687 shsMarket Capitalization€2.53 billionP/E RatioN/ADividend Yield1.26%Price TargetN/AConsensus RatingN/A Company Overview MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. Read More Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOR Stock News HeadlinesAsgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical ...April 14, 2026 | markets.businessinsider.comNovartis Gets Boost as Autoimmune Drug Suceeds in Key TrialsAugust 11, 2025 | msn.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 7 at 1:00 AM | Base Camp Trading (Ad)Novartis to close MorphoSys sites in Boston, Munich: reportDecember 19, 2024 | msn.comNovartis says 330 jobs hit as it closes MorphoSys sitesDecember 19, 2024 | msn.comNovartis raises sales guidance until 2028November 21, 2024 | msn.comAsymptomatic or Minimally Symptomatic MyelofibrosisNovember 4, 2024 | msn.comBiogen refreshes its C-suite; Novartis writes down MorphoSys assetsOctober 29, 2024 | finance.yahoo.comSee More Headlines MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at €67.25 at the beginning of the year. Since then, MOR shares have increased by 0.0% and is now trading at €67.25. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Bristol Myers Squibb (BMY), NVIDIA (NVDA), SolarEdge Technologies (SEDG), Gilead Sciences (GILD), AbbVie (ABBV) and Abbott Laboratories (ABT). Industry, Sector and Symbol Stock ExchangeETR SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolETR:MOR CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees730Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€12.24) Trailing P/E RatioN/A Forward P/E Ratio322.58 P/E Growth0.06Net Income-€460.81 million Net Margins-79.63% Pretax MarginN/A Return on Equity-183.80% Return on Assets-13.84% Debt Debt-to-Equity Ratio1,296.52 Current Ratio3.08 Quick Ratio3.49 Sales & Book Value Annual Sales€261.54 million Price / Sales9.68 Cash Flow€129.73 per share Price / Cash Flow0.52 Book Value€1.43 per share Price / Book47.05Miscellaneous Outstanding Shares37,662,715Free FloatN/AMarket Cap€2.53 billion OptionableNot Optionable Beta0.66 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (ETR:MOR) was last updated on 9/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOR Stock Alerts